Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.1B
86M shares
52-week range
$20.13 – $41.22
70% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | $87.2M | $125.8M | $176.0M |
| Cost of revenue | $29.1M | $31.4M | $40.8M |
| Gross profit | $58.1M | $94.4M | $135.2M |
| Gross margin | 66.6% | 75.1% | 76.8% |
| R&D | $35.9M | $43.5M | $64.9M |
| Operating income | −$72.9M | −$61.2M | −$64.1M |
| EBITDA | −$62.8M | −$65.5M | −$93.1M |
| Net income | −$95.7M | −$96.4M | −$116.8M |
| Net margin | -109.7% | -76.6% | -66.3% |
| EPS (diluted) | -1.94 | -1.53 | -0.32 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $230M | $-0.49 | $-0.54–$-0.44 | 4 |
| 2027 | $283M | $-0.26 | $-0.44–$-0.07 | 4 |
| 2028 | $343M | $0.06 | $-0.06–$0.17 | 2 |
| 2029 | $443M | $0.41 | $0.41–$0.42 | 1 |
Forward consensus · source: Financial Modeling Prep
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
www.heartflow.comNo one on the platform currently holds HTFL.
No tracked institution reports a position in HTFL as of their last filing.
No one on the platform has traded HTFL yet.
| $4.6B |
| — |
| PRGOPerrigo Company plc | $10.05 | +1.01% | $1.4B | — |
| PRVAPrivia Health Group, Inc. | $25.55 | -0.08% | $3.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Here are some of the most prominent themes that our team is focusing on: Healthcare: $OSCR $HNGE $UNH $JNJ $HTFL This Healthcare watchlist captures the vital rotating theme of mid-2026: smart money is spilling out of legacy defensive value into high-pricing-power digital health and clinical AI disruptors. The underlying fundamentals here are stellar. Digital MSK leader $HNGE just hiked its full-year 2026 growth outlook to a rampant 40% at its June 10 Investor Day. Meanwhile, AI coronary pioneer $HTFL raised its fiscal guidance following a blowout 41% YoY Q1 revenue jump on rapid product adoption. Concurrently, insurtech leader $OSCR is holding multi-year highs, while legacy staples like $UNH (navigating its recent FTC insulin settlement) and $JNJ reset to deep structural support. Are you sheltering in cash-cow defensive giants like $UNH, or accumulating high-growth AI health turnarounds like $HNGE and $HTFL on this necessary dip?
View on StockTwits ↗Weekend Video Part 1: US Watchlist Stocks – $CAVA, $DXCM, $HTFL (7mins) ▪️Login for full length weekend video (53mins) discussing all the important data for the Stage Analysis method (made famous in Stan Weinstein's classic book) https://www.stageanalysis.net/blog/1392110/stage-analysis-members-video-14-june-2026
View on StockTwits ↗New Blog Post: US Stocks Watchlist There are 22 stocks highlighted from the weekends US stocks watchlist scans – $CAVA, $DXCM, $HTFL https://www.stageanalysis.net/blog/1391908/us-stocks-watchlist-15-june-2026
View on StockTwits ↗$HTFL Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million? https://marketwirenews.com/stock/htfl/news/is-heartflow-stock-a-buy-after-an-institutional-inve-4787568265673733.html?utm_source=stocktwits
View on StockTwits ↗This $HTFL is one of the best stories out there. AI, Healthcare, coverage from insurers... Tackling the leading cause of death in the U.S. This is a $100+ stock in the coming 6-12 months IMHO(if company executes)
View on StockTwits ↗$HTFL will hit $35 to 36 next week, I was 31.50 this morning. very positive news
View on StockTwits ↗$HTFL A short position here is not unreasonable. It is extremely overvalued at anything above 20 dollars: -Valuation on EV/Sales ratio is through the roof. -Growth will be slowing sharply by next year. -While operating expenses expanding the sales team is skyrocketing. -Losses and cash burn are accelerating. -Cash is dwindling and they will need a capital raise in the near future. -Too many stock awards given cheaply in the money, and insiders can't stop selling their shares to retail. -Analysts have lowered their price targets post Q1 report.
View on StockTwits ↗$HTFL (-0.7% pre) Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance https://ooc.bz/l/102484
View on StockTwits ↗$HTFL PT raised to $37 from $35 at Wells Fargo - keeps Overweight rating
View on StockTwits ↗https://marketbeat.com/a/8655143/ $HTFL Heartflow Q1 Earnings Call Highlights
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-14-heartflow-inc-stock/ $HTFL Heartflow Earnings Transcript
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.